Prostatic Neoplasms, Castration-Resistant

"Prostatic Neoplasms, Castration-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

Descriptor ID	D064129
MeSH Number(s)	C04.588.945.440.770.500 C12.294.260.750.500 C12.294.565.625.500 C12.758.409.750.500
Concept/Terms	Prostatic Neoplasms, Castration-Resistant Prostatic Neoplasms, Castration-Resistant Castration-Resistant Prostatic Neoplasm Neoplasm, Castration-Resistant Prostatic Neoplasms, Castration-Resistant Prostatic Prostatic Neoplasm, Castration-Resistant Prostatic Neoplasms, Castration Resistant Androgen-Insensitive Prostatic Neoplasms Androgen Insensitive Prostatic Neoplasms Androgen-Resistant Prostatic Neoplasms Androgen Resistant Prostatic Neoplasms Prostatic Neoplasms, Hormone Refractory Hormone Refractory Prostatic Neoplasms Prostatic Neoplasms, Androgen-Independent Androgen-Independent Prostatic Neoplasm Neoplasm, Androgen-Independent Prostatic Neoplasms, Androgen-Independent Prostatic Prostatic Neoplasm, Androgen-Independent Prostatic Neoplasms, Androgen Independent Prostatic Neoplasms, Androgen-Insensitive Androgen-Insensitive Prostatic Neoplasm Neoplasm, Androgen-Insensitive Prostatic Neoplasms, Androgen-Insensitive Prostatic Prostatic Neoplasm, Androgen-Insensitive Prostatic Neoplasms, Androgen Insensitive Prostatic Neoplasms, Androgen-Resistant Androgen-Resistant Prostatic Neoplasm Neoplasm, Androgen-Resistant Prostatic Neoplasms, Androgen-Resistant Prostatic Prostatic Neoplasm, Androgen-Resistant Prostatic Neoplasms, Androgen Resistant Androgen-Independent Prostatic Neoplasms Androgen Independent Prostatic Neoplasms Castration-Resistant Prostatic Neoplasms Castration Resistant Prostatic Neoplasms Prostatic Cancer, Castration-Resistant Prostatic Cancer, Castration-Resistant Cancer, Castration-Resistant Prostatic Cancers, Castration-Resistant Prostatic Castration-Resistant Prostatic Cancers Prostatic Cancer, Castration Resistant Prostatic Cancers, Castration-Resistant Androgen-Insensitive Prostatic Cancer Androgen Insensitive Prostatic Cancer Androgen-Resistant Prostatic Cancer Androgen Resistant Prostatic Cancer Prostatic Cancer, Hormone Refractory Hormone Refractory Prostatic Cancer Prostatic Cancer, Androgen-Independent Androgen-Independent Prostatic Cancers Cancer, Androgen-Independent Prostatic Cancers, Androgen-Independent Prostatic Prostatic Cancer, Androgen Independent Prostatic Cancers, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Androgen-Insensitive Prostatic Cancers Cancer, Androgen-Insensitive Prostatic Cancers, Androgen-Insensitive Prostatic Prostatic Cancer, Androgen Insensitive Prostatic Cancers, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Androgen-Resistant Prostatic Cancers Cancer, Androgen-Resistant Prostatic Cancers, Androgen-Resistant Prostatic Prostatic Cancer, Androgen Resistant Prostatic Cancers, Androgen-Resistant Androgen-Independent Prostatic Cancer Androgen Independent Prostatic Cancer Castration-Resistant Prostatic Cancer Castration Resistant Prostatic Cancer

Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms, Castration-Resistant".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Genital Neoplasms, Male [C04.588.945.440]
Prostatic Neoplasms [C04.588.945.440.770]
Prostatic Neoplasms, Castration-Resistant [C04.588.945.440.770.500]
Male Urogenital Diseases [C12]
Genital Diseases, Male [C12.294]
Genital Neoplasms, Male [C12.294.260]
Prostatic Neoplasms [C12.294.260.750]
Prostatic Neoplasms, Castration-Resistant [C12.294.260.750.500]
Prostatic Diseases [C12.294.565]
Prostatic Neoplasms [C12.294.565.625]
Prostatic Neoplasms, Castration-Resistant [C12.294.565.625.500]
Urogenital Neoplasms [C12.758]
Genital Neoplasms, Male [C12.758.409]
Prostatic Neoplasms [C12.758.409.750]
Prostatic Neoplasms, Castration-Resistant [C12.758.409.750.500]

Below are MeSH descriptors whose meaning is related to "Prostatic Neoplasms, Castration-Resistant".

Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms, Castration-Resistant".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prostatic Neoplasms, Castration-Resistant" by people in this website by year, and whether "Prostatic Neoplasms, Castration-Resistant" was a major or minor topic of these publications.

Bar chart showing 177 publications over 13 distinct years, with a maximum of 24 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	5	1	6
2014	8	1	9
2015	11	0	11
2016	13	0	13
2017	14	1	15
2018	12	1	13
2019	10	0	10
2020	18	0	18
2021	14	0	14
2022	22	0	22
2023	24	0	24
2024	17	4	21
2025	1	0	1

Below are the most recent publications written about "Prostatic Neoplasms, Castration-Resistant" by people in Profiles.

Beer TM, George DJ, Shore ND, Winters-Stone K, Wefel JS, Verholen F, Srinivasan S, Ortiz J, Morgans AK. Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. Oncologist. 2025 Jul 04; 30(7).

View in: PubMed
Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 01; 131(1):e35612.

View in: PubMed
Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zsch?bitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024 Dec; 213:115078.

View in: PubMed
McManus HD, Dorff T, Morgans AK, Sartor O, Shore N, Armstrong AJ. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 2025 09; 28(3):672-683.

View in: PubMed
Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schl?rmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. 2025 Apr; 8(2):394-406.

View in: PubMed
Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 12 20; 42(36):4271-4281.

View in: PubMed
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fl?chon A, Wei XX, Mahammedi H, Roubaud G, ?tudentov? H, Nagarajah J, Mellado B, Montesa-Pino ?, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024 09 28; 404(10459):1227-1239.

View in: PubMed
Paller CJ, Zahurak ML, Mandl A, Metri NA, Lalji A, Heath E, Kelly WK, Hoimes C, Barata P, Taksey J, Garrison DA, Patra K, Milne GL, Anders NM, Nauroth JM, Durham JN, Marshall CH, Markowski MC, Eisenberger MA, Antonarakis ES, Carducci MA, Denmeade SR, Levine M. High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. Cancer Res Commun. 2024 08 01; 4(8):2174-2182.

View in: PubMed
George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2024 08 01; 7(8):e2429783.

View in: PubMed
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zsch?bitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer. Future Oncol. 2024; 20(29):2123-2135.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement